MedTrace Logo

Association of Genetic Polymorphisms With Atrial Fibrosis and Thrombogenic Substrate in Patients With Non-valvular Atrial Fibrillation

NCT03560219 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 225

Last updated 2018-06-19

No results posted yet for this study

Summary

Atrial fibrillation (AF) is the most frequently encountered cardiac arrhythmia. Emerging data suggests that common genetic variants are associated with the development of AF. The main feature of the structural remodelling in AF is atrial fibrosis and is considered the substrate for AF perpetuation. Genome-wide association studies suggest that AF-susceptibility variants may modulate atrial fibrosis. However, the association between atrial fibrosis and genetic polymorphisms in humans has not yet been specifically investigated. In this study, we plan to investigate the relationship between genetic polymorphisms, atrial fibrosis and other components of thrombogenic substrate in patients with non-valvular AF. Primary objectives of this study are to assess associations between (i) polymorphic genetic variants and atrial fibrosis (detected by magnetic resonance imaging), (ii) polymorphic genetic variants and components of thrombogenic substrate (inflammation, endothelial function, prothrombotic state, atrial functions).

Conditions

Interventions

DIAGNOSTIC_TEST

Biomarkers, Cardiac Magnetic Resonance Imaging, Echocardiography, Flow Mediated Dilatation, Genetic Analysis

Key variables that will be recorded include the following: * Clinical * Age * Gender * BMI * Diabetes Mellitus * Hypertension * Heart Failure * Ischemic Stroke / TIA * Thromboembolism * Coronary Artery Disease * Peripheral Arterial Disease * Glomerular Filtration Rate * Contrast-enhanced MRI o Presence and extent of atrial fibrosis * Biomarkers * IL-6 * CRP * D-dimer * Fibrinogen * Transthoracic Echocardiography * LA Volume Index (LAVI) * LA Strain, Global * LA Strain rate, Positive peak, Global * LA Strain rate, early negative peak, Global * LA Strain rate, late negative peak, Global * LA Emptying Fraction (LAEF) * LVH * LVEF * Endothelial function o FMD

Sponsors & Collaborators

  • Memorial Ankara Hospital

    lead OTHER

Eligibility

Min Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-01
Primary Completion
2019-12-01
Completion
2019-12-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03560219 on ClinicalTrials.gov